A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia (The DAYBREAK Study) Save

Date Added
August 23rd, 2016
PRO Number
Pro00057163
Researcher
Nicholas Milano

Silhouette
Keywords
Alzheimers, Dementia, Drug Studies
Summary

Subjects are being asked to volunteer for a research study because they have been diagnosed with Alzheimer's disease. Alzheimer's dementia is the most common form of dementia. It is a general term for memory loss and loss of other intellectual abilities that are serious enough to interfere with daily activities.

The purpose of this study is to see if the investigational drug, LY3314814 (study drug) can slow the progression of your Alzheimer's disease. In Part I of the study, subjects will either receive the study drug or placebo. After 78 weeks, all subjects will begin Part II where everyone is on the study drug.

Institution
MUSC
Recruitment Contact
John Keller
843-792-2209
kellej@musc.edu

Change_preferences

-- OR --

Create_login